CERo Therapeutics (CEROW) Stock Price, News & Analysis

Company Overview

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.

Key Stats

• Today's Range: $0.0114 to $0.0149
• 50-Day Range: $0.0114 to $0.0180
• 52-Week Range: $0.00 to $0.10
• Volume: 9,834 shs
• Average Volume: 85,721 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CEROW Stock Analysis - Frequently Asked Questions

How have CEROW shares performed this year?

CERo Therapeutics' stock was trading at $0.0083 on January 1st, 2025. Since then, CEROW stock has increased by 37.3% and is now trading at $0.0114.
View the best growth stocks for 2025 here.

How do I buy shares of CERo Therapeutics?

Shares of CEROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CEROW
• CIK: 1870404
• Web: www.cero.bio
• Phone: 650-407-2376
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A